Cell & Gene Therapy

Cell & Gene Therapy CRO Services for Complex Global Development

Premier Research (Premier) is a global CRO supporting cell, gene and RNA therapy innovators with integrated, end-to-end services spanning regulatory, nonclinical, CMC, clinical operations, safety, data, quality, and commercial strategy. Our senior-led, multidisciplinary team is purpose-built for CGT. Our approach is rooted in three pillars: a dedicated focus on advanced therapies; a tailored, high-touch approach with global reach; and integrated regulatory and clinical expertise. Together, these strengths help sponsors mitigate risks and navigate complexities to maximize asset value and move therapies closer to patients.

100+ CGT projects conducted in last 5 years
70% Of projects in Phase II/III
400 Sites initiated
1,000+ Patients reached

Cell & Gene Therapy Capabilities

Regulatory, Nonclinical & IND-Enabling Strategy

Guidance on nonclinical planning, IND/CTA strategy and preparation, accelerated approval opportunities (Fast Track, RMAT and Breakthrough Designations), and quality-driven regulatory strategies that facilitate smooth agency interactions and submission readiness.

Learn More

Technical CMC Services

Comprehensive and phase-appropriate chemistry, manufacturing, and controls (CMC) services built on quality-by-design principles, including biologics submission assessment, target product profiles, risk management, scale-up and post-approval strategy.

Learn More

Clinical Trial Design, Operations & Site Support

End-to-end CGT trial delivery supported by rigorous GxP-compliant processes and quality oversight from protocol development and site activation through logistics management, patient engagement, retention, and long-term follow-up.

Learn More

Medical Monitoring and PV Strategy

Integrated monitoring, pharmacovigilance, immunogenicity risk management, and long-term follow-up by CGT specialists for proactive safety oversight and rapid quality-driven signal detection that ensures patient protection throughout development.

Learn More

Integrated Guidance for Navigating CGT Complexity

Cell and gene therapy development requires more than conventional clinical trial execution. These programs often involve evolving regulatory expectations, specialized CMC considerations, limited patient populations, invasive or complex administration procedures, immunogenicity and patient safety concerns, high-touch site requirements, and long-term follow-up obligations. Success requires a development partner with specialized advanced therapy expertise, strategic guidance, and the flexibility to adapt to each program's unique needs. Premier brings together CGT-specialized regulatory, clinical, medical, CMC, nonclinical, data, safety, and operational experts to help sponsors move from early development planning through clinical delivery. Our senior-led teams have deep CGT development expertise. They combine a high-touch operating model with seamless collaboration across all critical functions to help sponsors navigate challenges, make informed decisions, and maximize asset value.

Trial Logistics

Autologous and allogeneic cell therapy programs require precise coordination across patients, sites, couriers, manufacturers, labs, and treatment teams. Leveraging a cross-functional delivery team, Premier manages operational complexity while protecting patient safety and product integrity.

  • Modalities Supported: CAR-T, NK cell, stem cell, tumor-infiltrating lymphocytes, autologous and allogenic approaches
  • Logistics Managed: Vein-to-vein, apheresis scheduling, cryopreservation planning, chain-of-custody and chain-of-identity tracking

Data Capture, Oversight and Transparency

CGT trials demand rigorous attention to data capture strategy and monitoring. Guided by operational and medical experts, Premier utilizes data capture systems tailored for CGT studies to customize tracking and support centralized data oversight, reporting, and governance.

Adaptive analytics enhance strategic decision-making, improve transparency, and enable timely evaluation of key safety, efficacy, quality, and compliance metrics.

Patient-Centered Site Strategy

The site landscape is competitive and diverse, spanning academic centers, community sites, and CGT-naïve locations with varying training and operational needs. To be successful, a trial requires specially trained sites with the appropriate infrastructure, staffing, biosafety readiness, logistics coordination, and patient support capabilities to execute advanced therapy trials safely and consistently.

Premier delivers patient-centered site engagement and training strategies that reduce start-up friction, support administration, simplify follow-up, and improve retention across rare disease, oncology, neurology, and other CGT indications.

Strategic Development-to-Commercial Planning

Premier’s focus is on maximizing the value of every asset—for both sponsors and patients—through comprehensive planning that aligns nonclinical and clinical development with regulatory and commercial objectives. As a development partner, we bring commercial insight early and often in the development process to create a more efficient path from development through launch.

From market analysis and target product profiles to reimbursement strategy and commercialization planning, we provide robust commercial assessments that support informed decisions, reduce risk, and position programs for success.

Cell & Gene Therapy

Meet the Experts

Kenneth Ndugga-Kabuye, M.D., FACMG
Kenneth Ndugga-Kabuye, M.D., FACMG Vice President, Cell & Gene Therapy

Dr. Ken Ndugga-Kabuye is Vice President, Cell & Gene Therapy at Premier Research. He brings direct experience supporting drug development candidates for clinical studies leveraging innovative approaches in the treatment of disease, inclusive of cell and gene therapies, synthetic biotics, RNA therapies, and enzyme replacement therapies. In previous roles, Dr. Ndugga-Kabuye has supported CRO and biotechnology clients in the ATMP space. Dr. Ndugga-Kabuye is a clinical geneticist with residency and fellowship training in medical genetics and genomics from the University of Washington in Seattle, WA, US. He is board certified by the American Board of Medical Genetics and Genomics in Clinical Genetics and Genomics. He holds a medical license in Washington State and California. He is a Diplomate of the American Board of Medical Genetics and Genomics. He is a member of the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the American College of Medical Genetics (ACMG), the African Society of Human Genetics (AfSHG), the American Medical Association (AMA) and the American Academy of Pediatrics (AAP).

Learn more
Jessica Merryfield
Jessica Merryfield Vice President, Project Delivery, Cell & Gene Therapy

Jessica Merryfield has been involved in global clinical research for more than 20 years, specializing in rare diseases for the last 10 years. As vice president, gene and cell therapy; Ms. Merryfield advises, consults, plans, and directs the design and strategy for prospective and ongoing gene and cell therapy studies. In her role, she provides operational excellence by driving best practices, identifying global needs for innovation and improvements, and leading Premier’s Continuous Learning Program for Advanced Therapeutics. Through stakeholder engagement and cross-functional management, Ms. Merryfield operates at a strategic support level for complex, critical therapeutically aligned programs. She coordinates strategic direction and delivery for gene and cell therapy with Premier’s innovative partners, including regulatory and statistical consulting, therapeutic experts, patient engagement, and strategic development. Ms. Merryfield has extensive experience in phase 1-4 studies, including autosomal, neurological, metabolic, and hematology disease utilizing innovative precision medicine technologies. Her key experience areas include pediatrics, rare/ultra-rare disease, cardiology, immunology/autoimmune disorders, dermatology, and CNS.

Learn more
Paulla Dennis
Paulla Dennis Executive Director, Program Strategy, Rare Disease, Pediatrics, Cell & Gene Therapy

Paulla Dennis has been dedicated to rare disease and pediatric clinical research for more than 25 years, specializing in gene therapy for the last 10+ years. She is highly experienced in operational delivery after spending 17 years at a pediatric hospital running the Clinical Research Services group, where she delivered pivotal studies in several rare pediatric disorders inclusive of gene therapies. Paulla has an additional 8 years’ experience in the CRO setting in startup project management as well as in program strategy, delivering rare, pediatric disease and advanced therapies studies. As Executive Director, Program Strategy, Paulla advises, consults, plans, and directs the design and strategy for prospective and ongoing rare, pediatric, and gene and cell therapy studies. In her current role, she provides strategies and solutions for operational excellence in this complex clinical research setting with a focus on patient and family pathway planning and comprehensive site assessment and educational support. Paulla has extensive experience in phase 1-4 studies in a global setting, including autosomal, neurological, metabolic, and endocrine diseases. Her key experience areas include rare/ultra-rare disease, pediatrics, gene therapies, and neurological (neuropsychological, neurodegenerative, and neuromuscular) indications.

Learn more
Greg Meyer, RAC, CQA
Greg Meyer, RAC, CQA Vice President, Regulatory Affairs

Greg Meyer has been in the pharma, biopharma and medical device industry for over 30 years and has gained regulatory approvals in more than 20 countries. He has represented companies during numerous interactions with the FDA, European national and EU regulators, and the Australian TGA and has worked on the development, submission, and commercialization of NMEs and 505(b)(2) products in oncology, neurology, and dermatology. His specialty areas include, cell and gene therapy, biologics and drug-device combination products.

Learn more
Olu Aloba, Ph.D.
Olu Aloba, Ph.D. Vice President, CMC Services

Dr. Aloba has more than 25 years of leadership experience in pharmaceutical research and development, pharmaceutical technology, and regulatory strategy. He is a subject matter expert in drug product development, with special expertise in the application of quality-by-design (QbD) to formulation and process development, analytical development, and development strategy. He is a registered pharmacist and holds a US Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society. Dr. Aloba joined Premier in 2014 and, in his current role, leads Premier’s Chemistry Manufacturing and Controls (CMC) service offerings focusing on pharmaceutical development strategizing, planning, execution, and documentation in support of drug development programs for Premier’s clients. He also serves as senior technical advisor on Premier’s drug, device, and biologics initiatives and is responsible for continuing development of the pharmaceutical quality expertise, knowledgebase, and policy at Premier.

Learn more
Angi Robinson
Angi Robinson Senior Vice President, Specialty Areas (Rare Disease, Pediatrics, Cell & Gene Therapy)

Angi Robinson has been designing and conducting specialty studies, including pediatric and rare disease studies, for more than 22 years. She has provided strategy, oversight, and full management support for rare disease studies at Premier Research for over 18 years, including global programs in ultra-rare indications. Ms. Robinson has a thorough understanding of drug development with extensive supervisory experience and management in conducting registrational-enabling clinical trials for orphan drugs. Ms. Robinson’s experience encompasses complex study designs such as PK/PD and adaptive design, and she has worked with products granted expedited designations by the agencies like FDA Fast Track, Breakthrough Therapy and PRIME designations — including advanced medicines. Specifically in orphan drugs, Ms. Robinson has supported eight products resulting in FDA and EMA approval. Ms. Robinson earned a bachelor’s degree in cell and molecular biology from Tulane University in New Orleans, LA.

Learn more

Related Resources

FAQs

Find answers to common questions about our cell and gene therapy expertise.

Ready to Get Started?
So Are We.

Connect With Us